Europe

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Digital

Cracking the code: How European biotechs can win in the US m...

At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for emerging pharma and biotech...

R&D

How Europe can harness the full potential of biosimilars

Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.

Sales & Marketing

Tariffs, pharma, and patients: A Q&A with Orr Inbar

In order to discuss the current unsettled landscape, and just how tariffs might affect patients, pharmaphorum spoke with Orr Inbar of QuantHealth.

R&D

No longer the little fish: How Europe is holding its own thr...

It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.

News

EC clears first treatment for high-risk smouldering multiple...

Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX